Table 1.
Summary of recent studies of HCV + heart transplantation
| Author/year | Design | HCV + donor NAT profile | HCV treatment protocol (# patients) | Outcomes |
|---|---|---|---|---|
| Gottlieb et al., 2017 [18] | Case report | 1 NAT + | Pre-emptive: SOF/VEL (1) | SVR12: 1/1 Survival: 1/1 at 1 year |
| Schlendorf et al., 2018 [19] | Single-center prospective cohort study | 11 NAT + , 2 HCV Ab + NAT − | No HCV viremia/therapy: 4 Pre-emptive: LDV/SOF (7), SOF/VEL (2) | SVR12: 8/9 Survival: 12/13 at 6 months |
| Woolley et al., 2019 [20] | Single-center open label pilot trial | 7 NAT + | Prophylactic: SOF/VEL (7) | SVR12: 7/7 Survival: 7/7 at 6 months |
| McLean et al., 2019 [23] | Single-arm pilot trial | 10 NAT + (all HCV genotype 1) | Pre-emptive: EBR/GZR (10) | SVR12: 9/10 Survival: 9/10 at 8 months |
| Aslam et al., 2019 [22] | Retrospective case series | 19 NAT + , 2 HCV Ab + NAT − | No HCV viremia/therapy: 2 Pre-emptive: G/PIB (14), SOF/VEL (2), EBR/GZR (2), LDV/SOF (1) | SVR12: 18/18 Survival: 19/21 at 12 months |
| Bethea et al., 2019 [21] | Single-center open label trial | 20 NAT + , 5 HCV Ab + NAT − | No HCV viremia/therapy: 5 Prophylactic (NAT + donors): G/PIB (20) | SVR12: 20/20 Survival: 25/25 at 10.7 months |
| Schlendorf et al., 2019 [24•] | Single-center prospective cohort study | 70 NAT + , 10 HCV Ab + NAT − | No HCV viremia/therapy: 13 Pre-emptive (55): LDV/SOF (27), SOF/VEL (16), G/PIB (12) Pending DAAT initiation/completion: 12 | SVR12: 37/55 (13 pending) Survival: 61/67 at 12 months |
| Madan et al., 2019 [25•] | UNOS database retrospective cohort study (2015–2018) | 118 NAT + , 86 HCV Ab + NAT − | Not reported | Survival: 91% at 1 year |
| Kilic et al., 2020 [26•] | UNOS database retrospective cohort study (2016–2018) | 194 NAT + , 137 HCV Ab + NAT − , 12 NAT unknown | Not reported | Survival: 90% at 1 year (HCV Ab + vs. HCV Ab −); 92% at 1 year (NAT + vs. NAT −) |
| Feld et al., 2020 [34] | Single-center single-arm pilot trial | 6 NAT + | Prophylactic: G/PIB (6) | SVR12: 6/6 Survival: 6/6 at 36 weeks |
| Morris et al., 2020 [37] | Single-center retrospective cohort study | 23 NAT + , 2 HCV Ab + NAT − | Pre-emptive: G/PIB (15), SOF/VEL (5), LDV/SOF (2) | SVR12: 21/22 Survival: 25/25 at 220 days |
| Kapila et al., 2020 [36] | Single-center single-arm trial | 7 NAT + | Pre-emptive: LDV/SOF (4), G/PIB (3) | SVR 12: 6/7 (1 pending) |
| Reyentovich et al., 2020 [35] | Single-center open-label prospective trial | 22 NAT + | Prophylactic: G/PIB (22) | SVR12: 22/22 Survival: 21/22 at 1 year |
EBR, elbasvir; G, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; NAT, nucleic acid amplification testing; PIB, pibrentasvir; SOF, sofosbuvir; SVR12, sustained viral response 12 weeks after DAAT completion; UNOS, United Network for Organ Sharing; VEL, velpatasvir.